Platelet Transfusion for Patients With Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*

Schiffer, Charles A.; Anderson, Kenneth C.; Bennett, Charles L.; Bernstein, Steven; Elting, Linda S.; Goldsmith, Miriam E.; Goldstein, Michael B.; Hume, Heather; McCullough, J; McIntyre, Rosemary E.; Powell, Bayard L.; Rainey, John M.; Rowley, Scott D.; Rebulla, Paolo; Troner, M.; Wagnon, Alton H.

doi:10.1200/jco.2001.19.5.1519

Cited by 525 publications

(341 citation statements)

References 136 publications

Supporting

Mentioning

325

Contrasting

Unclassified

Order By: Relevance

“…[16][17][18] There is a long-standing controversy in the scientific community of hematologists and oncologists as to whether standard prophylactic platelet transfusions are necessary or whether this strategy should better be replaced by a therapeutic transfusion strategy. 10,17,[19][20][21][22] During the last 20 years, the recommendations of the American Society of Clinical Oncology reduced the trigger for prophylactic platelet transfusion from 20 Â 10 9 /l down to 10 Â 10 9 /l for thrombocytopenia following intensive chemotherapy or after hematopoietic stem cell transplantation. 10 The decision to administer platelet transfusions should incorporate individual clinical characteristics of the patient and not simply be a reflex to the morning platelet count.…”

Section: Discussionmentioning

confidence: 99%

“…10,17,[19][20][21][22] During the last 20 years, the recommendations of the American Society of Clinical Oncology reduced the trigger for prophylactic platelet transfusion from 20 Â 10 9 /l down to 10 Â 10 9 /l for thrombocytopenia following intensive chemotherapy or after hematopoietic stem cell transplantation. 10 The decision to administer platelet transfusions should incorporate individual clinical characteristics of the patient and not simply be a reflex to the morning platelet count. Platelet transfusions are expensive and associated with a number of side effects.…”

Section: Discussionmentioning

confidence: 99%

“…9 Therefore, the American Society of Clinical Oncology recently published clinical practice guidelines with a prophylactic platelet transfusion trigger of 10 Â 10 9 /l for acute leukemia and hematopoietic cell transplantation. 10 The use of peripheral blood stem cells instead of bone marrow in autologous transplants has substantially shortened the duration of severe thrombocytopenia. It is still not known whether a prophylactic platelet transfusion strategy is necessary, or whether a therapeutic transfusion strategy is as safe and more cost effective.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation

Wandt

Schaefer‐Eckart

Frank

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

Prophylactic platelet transfusions are considered as standard in most hematology centers, but there is a long-standing controversy as to whether standard prophylactic platelet transfusions are necessary or whether this strategy could be replaced by a therapeutic transfusion strategy. In 106 consecutive cases of patients receiving 140 autologous peripheral blood stem cell transplantations, we used a therapeutic platelet transfusion protocol when patients were in a clinically stable condition. Platelet transfusions were only used when relevant bleeding occurred (more than petechial). Median duration of thrombocytopenia o20 Â 10 9 /l and o10 Â 10 9 /l was 6 and 3 days, which resulted in a total of 989 and 508 days, respectively. In only 26 out of 140 transplants (19%), we observed clinically relevant bleeding of minor or moderate severity. No severe or lifethreatening bleeding was registered. The median and mean number of single donor platelet transfusions was one per transplant (range 0-18). One-third of all transplants, and 47% after high-dose melphalan could be performed without any platelet transfusion. Compared with a historical control group, we could reduce the number of platelet transfusions by one half. This therapeutic platelet transfusion strategy can be performed safely resulting in a considerable reduction in prophylactic platelet transfusions.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation

Wandt

Schaefer‐Eckart

Frank

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Rationale No RCTs of prophylactic platelet transfusion in septic or critically ill patients exist. Current recommendations and guidelines for platelet transfusion are based on clinical trials of prophylactic platelet transfusion in patients with therapy-induced thrombocytopenia (usually leukemia and stem cell transplant) [320][321][322][323][324][325][326][327]. Thrombocytopenia in sepsis is likely due to a different pathophysiology of impaired platelet production and increased platelet consumption.…”

mentioning

confidence: 99%

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

et al. 2017

View full text Add to dashboard Cite

Objective: To provide an update to "Surviving Sepsis Campaign Guidelines for Management of Sepsis and Septic Shock: 2012". Design:A consensus committee of 55 international experts representing 25 international organizations was convened. Nominal groups were assembled at key international meetings (for those committee members attending the conference). A formal conflict-of-interest (COI) policy was developed at the onset of the process and enforced throughout. A stand-alone meeting was held for all panel members in December 2015. Teleconferences and electronic-based discussion among subgroups and among the entire committee served as an integral part of the development. Methods:The panel consisted of five sections: hemodynamics, infection, adjunctive therapies, metabolic, and ventilation. Population, intervention, comparison, and outcomes (PICO) questions were reviewed and updated as needed, and evidence profiles were generated. Each subgroup generated a list of questions, searched for best available evidence, and then followed the principles of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system to assess the quality of evidence from high to very low, and to formulate recommendations as strong or weak, or best practice statement when applicable.

show abstract

“…12 The usual dose of platelets is 4 to 6 units of random donor platelets and one unit of single donor aphaeresis platelets. In an attempt to reduce platelet transfusion Recombinant human interleukin11 (Oprelvekin) was approved by the FDA and reduced the need for platelet transfusion but was associated with a wide range of cardio pulmonary side effects.…”

Section: Managementmentioning

confidence: 99%

Toxicities of anticancer drugs and its management

Remesh

2012

Int J Basic Clin Pharmacol

122

View full text Add to dashboard Cite

One of the characteristics that distinguish anticancer agents from other drugs is the frequency and severity of side effects at therapeutic doses. Most cytotoxic drugs target rapidly multiplying cells and the putative targets are the nucleic acids and their precursors, which are rapidly synthesised during cell division. Many solid tumours have a lower growth fraction than the normal bone marrow, gastro intestinal lining, reticuloendothelial system and gonads. Drugs affect these tissues in a dose dependant manner and there is individual susceptibility also. So toxicities are more frequently associated with these tissues. The side effects may be acute or chronic, self-limited, permanent, mild or potentially life threatening. Management of these side effects is of utmost importance because they affect the treatment, tolerability and overall quality of life. This paper gives an overview of different toxicities of anticancer drugs and its management. [Int J Basic Clin Pharmacol 2012; 1(1.000): 2-12

show abstract

Platelet Transfusion for Patients With Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*

Abstract: American Society of Clinical Oncology

Cited by 525 publications

References 136 publications

A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation

A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

Toxicities of anticancer drugs and its management

Contact Info

Product

Resources

About